Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.50 |
| ▸ | CA1 | P00915 | 4/20 | 0.42 |
| ▸ | CA2 | P00918 | 4/20 | 0.42 |
| ▸ | CA12 | O43570 | 3/20 | 0.42 |
| ▸ | CA7 | P43166 | 3/20 | 0.42 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.41 |
| ▸ | MAOB | P27338 | 1/20 | 0.41 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.41 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.41 |
| ▸ | RELA | Q04206 | 1/20 | 0.41 |
| ▸ | CA9 | Q16790 | 2/20 | 0.41 |
| ▸ | BTK | Q06187 | 1/20 | 0.40 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 3/20 | 0.40 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | APOB | P04114 | 1/20 | 0.38 |
| ▸ | MTTP | P55157 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20826329 | 0.84 | EPHX2 (0.51) | EPHX2CA1CA2CA12CA7 | |
| SCHEMBL390212 | 0.84 | EPHX2 (0.51) | EPHX2CA1CA2CA12CA7 | |
| SCHEMBL30748079 | 0.83 | EPHX2 (0.50) | EPHX2CA1CA2CA12CA7 | |
| SCHEMBL31324550 | 0.83 | EPHX2 (0.50) | EPHX2CA1CA2CA12CA7 | |
| SCHEMBL1545004 | 0.83 | EPHX2 (0.50) | EPHX2CA1CA2CA12CA7 | |
| SCHEMBL30267146 | 0.83 | EPHX2 (0.50) | EPHX2CA1CA2CA12CA7 | |
| SCHEMBL5598167 | 0.83 | EPHX2 (0.50) | EPHX2CA1CA2CA12CA7 | |
| SCHEMBL1545000 | 0.83 | EPHX2 (0.50) | EPHX2CA1CA2CA12CA7 | |
| SCHEMBL29878515 | 0.83 | EPHX2 (0.50) | EPHX2CA1CA2CA12CA7 | |
| SCHEMBL28926914 | 0.83 | EPHX2 (0.50) | EPHX2CA1CA2CA12CA7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2024-05-16 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2023-10-10 | — | — | US | disclosed |
| US-20220332708-A1 | SULFONAMIDE COMPOUNDS AS CARDIAC SARCOMERE ACTIVATORS | CYTOKINETICS INC (US) | 2022-10-20 | — | — | US | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2022-09-08 | — | — | US | disclosed |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | CYTOKINETICS, INC. (US) | 2022-04-12 | — | — | US | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | AMGEN INC. (US) | 2022-02-22 | — | — | US | disclosed |
| US-20200223830-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | CYTOKINETICS, INC. | 2020-07-16 | — | — | US | disclosed |
| US-20200223829-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2020-07-16 | — | — | US | disclosed |
| WO-2019055590-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. (US) | 2019-03-21 | — | — | WO | disclosed |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | AMGEN INC. | 2019-03-14 | — | — | US | disclosed |
| US-8871796-B2 | Diaryl ether derivatives as notch sparing gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-8871796-B2 | Diaryl ether derivatives as notch sparing gamma secretase inhibitors | MERCK SHARP & DOHME CORP. (US) | 2014-10-28 | — | — | US | disclosed |
| US-20130053386-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME LLC | 2013-02-28 | — | — | US | disclosed |
| EP-2488031-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | Merck Sharp & Dohme Corp. (US) | 2012-08-22 | — | — | EP | disclosed |
| WO-2011046774-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-21 | — | — | WO | disclosed |
| WO-2011046774-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | MERCK SHARP & DOHME CORP. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11254658-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | EPHX2 4131/4885CA1 3966/4885CA2 257/4885 |
| US-20200223830-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | EPHX2 4131/4885CA1 3966/4885CA2 257/4885 |
| US-11780826-B2 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | EPHX2 4131/4885CA1 3966/4885CA2 257/4885 |
| US-20240158372-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | EPHX2 4131/4885CA1 3966/4885CA2 257/4885 |
| US-20200223829-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | EPHX2 4131/4885CA1 3966/4885CA2 257/4885 |
| US-20220332708-A1 | SULFONAMIDE COMPOUNDS AS CARDIAC SARCOMERE ACTIVATORS | TNNT2, TNNI3, MYLK2 | EPHX2 4573/4885CA1 4057/4885CA2 597/4885 |
| US-20190077793-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | EPHX2 4131/4885CA1 3966/4885CA2 257/4885 |
| US-20130053386-A1 | DIARYL ETHER DERIVATIVES AS NOTCH SPARING GAMMA SECRETASE INHIBITORS | BACE1, BACE2, GSAP | EPHX2 79/4885CA1 1650/4885CA2 4203/4885 |
| US-20220281850-A1 | BISAMIDE SARCOMERE ACTIVATING COMPOUNDS AND USES THEREOF | TNNI3, TNNT2, TNNC1 | EPHX2 4131/4885CA1 3966/4885CA2 257/4885 |
| US-11299479-B1 | Bisamide sarcomere activating compounds and uses thereof | TNNI3, TNNT2, TNNC1 | EPHX2 4131/4885CA1 3966/4885CA2 257/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.